The Future of Biosimilars - A Case of Untapped Potential?

Gerald Clarke
Posted: 03/25/2014

The patents on a majority of the top-selling biologic drugs currently on the market will have expired by 2020, an amount which may be equivalent to $67 billion. Can we expect then a rush of biosimilar products to the market, drastically lowering spend on biological drugs? If current trends are anything to go by, the answer is maybe not.

To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

Gerald Clarke
Posted: 03/25/2014

Pharma IQ Members


United States
February 25 - 27, 2018
Hilton Toronto/Markham Suites Conference Centre & Spa, Markham, Ontario, Canada
February 25 - 28, 2018